92.12 -0.14 (-0.15%)
After hours: 5:19PM EDT
|Bid||92.01 x 1000|
|Ask||92.25 x 800|
|Day's Range||92.05 - 93.33|
|52 Week Range||83.19 - 125.86|
|PE Ratio (TTM)||22.90|
|Earnings Date||Nov 2, 2018|
|Forward Dividend & Yield||3.84 (4.01%)|
|1y Target Est||109.45|
SAN FRANCISCO , Sept. 21, 2018 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in AbbVie Inc. (NYSE: ABBV) to the firm's investigation into possible disclosure violations. If you purchased ...
Drug companies say the services, such as nurses and reimbursement assistance, help doctors and patients. Inc., accusing the company of providing kickbacks in the form of nursing support and insurance assistance to prompt doctors to write prescriptions for its arthritis drug Humira. Altogether, the federal investigations, whistleblower lawsuits and California case suggest that the drug industry’s growing provision of free services is starting to draw the same kind of attention that had been trained on once-common company sales practices such as lavishing high-prescribing doctors with fancy dinners and trips.
NEW YORK, Sept. 21, 2018-- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving ...
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AbbVie Inc. (“AbbVie” or “the Company”) (NYSE: ABBV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of AbbVie Inc. (“AbbVie” or the “Company”) (ABBV) resulting from allegations that AbbVie and/or its executives may have issued materially misleading business information to the investing public. If you purchased AbbVie securities, and/or would like to discuss your legal rights and options, please visit AbbVie Shareholder Investigation or contact Daniel Sadeh toll free at (877) 779-1414 or email@example.com.
Currently, legal marijuana is one of the most exciting investment sectors. After demonstrating evidence of being technically overbought, Cronos Group (NASDAQ:CRON) put up a remarkable performance, up 19% in just two days of trading. For the year, CRON stock has gained 70%.
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of AbbVie Inc. resulting from allegations that AbbVie may have issued materially misleading business information to the investing public.
- If approved by the European Commission (EC), VENCLYXTO® plus rituximab would be the first chemotherapy-free combination regimen with a fixed duration of treatment for patients with chronic lymphocytic leukemia who have received at least one prior therapy. NORTH CHICAGO, Ill., Sept. 21, 2018 /PRNewswire/ -- AbbVie (ABBV), a research-based global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for VENCLYXTO® (venetoclax tablets) in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who have received at least one prior therapy.
Law Offices of Howard G. Smith announces an investigation on behalf of AbbVie Inc. investors concerning the Company and its officers’ possible violations of federal securities laws.
NEW YORK, Sept. 20, 2018-- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead ...
NEW YORK , Sept. 20, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of AbbVie ...
Europe has approved a fifth copy of AbbVie's (ABBV.N) $18-billion (£13.7 billion)-a-year biologic drug Humira – the world's best-selling prescription medicine – ramping up competition among makers of less-expensive biotech drugs. Mylan (MYL.O) and Fujifilm Kyowa Kirin Biologics said on Thursday they had won a European Commission green light to market their version of the injectable medicine, known as Hulio.
Europe has approved a fifth copy of AbbVie's $18-billion-a-year biologic drug Humira – the world's best-selling prescription medicine – ramping up competition among makers of less-expensive biotech drugs. Mylan and Fujifilm Kyowa Kirin Biologics said on Thursday they had won a European Commission green light to market their version of the injectable medicine, known as Hulio.
Mylan and Fujifilm Kyowa Kirin Biologics said on Thursday they had won European approval to market a cheaper copy of AbbVie's $18-billion-a-year biologic drug Humira, the world's best-selling prescription ...
AbbVie's (ABBV) shares fall on a lawsuit by California insurance department accusing it of giving illegal kickbacks to doctors for prescribing Humira.
California's insurance commissioner alleges AbbVie gave "illegal kickbacks to health care providers to prescribe" its Humira rheumatoid arthritis drug.
NEW YORK , Sept. 19, 2018 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) has been investigating claims on behalf of investors of AbbVie Inc. ("AbbVie" or the "Company") ...
The S&P 500 had been noticeably higher mid-session, ultimately dragged down by General Mills (NYSE:GIS) and AbbVie (NYSE:ABBV). The former fell 7.6% following a disappointing earnings report, while AbbVie lost 2.9% of its value on Tuesday after regulators accused the company of offering illegal kickbacks. Stocks charts of Procter & Gamble (NYSE:PG), BorgWarner (NYSE:BWA) and DISH Network (NASDAQ:DISH) are your best bets.
Let's check out the Yahoo Finance charts of the day. Abbvie (ABBV): Shares are down in early trade, at around .67%. Abbvie is being sued by an insurance regulator in California for allegedly giving kickbacks to health-care providers for prescribing Humira, an arthritis drug. AutoNation (AN): Shares up here, at around 2.5%. The company's CEO, Mike Jackson, will step down from his role in 2019 to become the company's executive chairman. AutoNation is searching to find its next chief executive. E-Trade (ETFC): Shares up here, around 2.7%. The online broker's stock was upgraded to "buy" from "hold", citing an attractive valuation as well as the company's scale and revenue diversity at a time when competition in the space heats up. For more on today's big stock movers check out the Final Round, live at 3:30 p.m. ET, right here on Yahoo Finance.